SARAH HAZANY: Open Payments
NPI 1093253437 · NEWBURY PARK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,245 in 51 payments from 14 companies in 2025. Trend: 2023 $1,949 · 2024 $1,444 · 2025 $1,245
Food & beverage: $1,245
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $250 |
| Otsuka America Pharmaceutical, Inc. | 6 | $161 |
| Alkermes, Inc. | 5 | $125 |
| Bausch Health US, LLC | 5 | $115 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $113 |
| Lundbeck LLC | 4 | $96 |
| Axsome Therapeutics, Inc. | 4 | $88 |
| Neurocrine BioSciences, Inc. | 2 | $69 |
| UCB, Inc. | 1 | $48 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
Products named: REXULTI, VRAYLAR, ARISTADA, APLENZIN, CAPLYTA, Auvelity, INGREZZA, Bimzelx.
Industry payments across CA — which companies pay providers there.
